Caribou Biosciences has filed for an initial public offering of $100 million, reported StreetInsider.
The company is working on applying its hybrid RNA-DNA CRISPR platform (chRDNA) toward the development of next-generation, genome-edited cell therapies.
Caribou says its chRDNA technology has demonstrated superior specificity and high efficiency in preclinical studies, enabling multiple, precise genomic edits, while maintaining genomic integrity.










(All Rights Reserved)